Cyclic compounds (2)
Alpha blockers (1)
Alpha-2 blockers (1)
Organic compound (1)
Sigma Aldrich (3)
AK Scientific (1)
Oakwood Chemical (1)
TCI Chemicals (1)
1-Aminocyclopropanecarboxylic acid (22059-21-8)
1-aminocyclopropane-1-carboxylic acid · 1-aminocyclopropane-1-carboxylic acid, 14C-labeled · ACC acid
1-Aminocyclopropane-1-carboxylic acid (ACC) is a disubstituted cyclic α-amino acid in which a three-membered cyclopropane ring is fused to the Cα atom of the amino acid. ACC plays an important role in the biosynthesis of the plant hormone ethylene. It is synthesized by the enzyme ACC synthase ( EC 18.104.22.168) from methionine and converted to ethylene by ACC oxidase (EC 22.214.171.124).
R 11,333 · bromperidol, 82Br-labeled · Tesoprel
Bromperidol (marketed as Bromidol, Bromodol) is a butyrophenone derivative. It is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1966.
3,4-Dihydroxystyrene (DHS) is a centrally-acting inhibitor of the enzyme phenylalanine hydroxylase (PH). It is likely that DHS and other PH inhibitors will never have clinical applications on account of their capacity for inducing hyperphenylalaninemia and phenylketonuria.
1,3,5-tris(3-isocyanato-4-methylphenyl)-1,3,5-triazinane-2,4,6-trione (26603-40-7, 8060-82-0)
brobenzoxaldine, broxyquinoline drug combination · Intestopan · Enteroquin
Aptiganel (Cerestat; CNS-1102) is an unsuccessful drug candidate which acts as a noncompetitive NMDA antagonist, and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke. It has neuroprotective effects and was researched for potential use in the treatment of stroke, but despite positive results in animal studies, human trials showed limited efficacy, as well as undesirable side effects such as sedation and hallucinations, and clinical development was ultimately not continued. The drug's failure led to the collapse of Cambridge Neuroscience in 1998 and its eventual sale to CeNeS Pharmaceuticals in 2000.
Temozolomide (TMZ; brand names Temodar and Temodal and Temcad) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.